enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Dexlansoprazole - Wikipedia

    en.wikipedia.org/wiki/Dexlansoprazole

    Dexlansoprazole, is a medication which reduces stomach acid. [3] It is used to treat gastroesophageal reflux disease. [3] Effectiveness is similar to other proton pump inhibitors (PPIs). [4]

  3. Vonoprazan - Wikipedia

    en.wikipedia.org/wiki/Vonoprazan

    Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. [2] [1] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.

  4. Category : Drugs developed by Takeda Pharmaceutical Company

    en.wikipedia.org/wiki/Category:Drugs_developed...

    Pages in category "Drugs developed by Takeda Pharmaceutical Company" The following 59 pages are in this category, out of 59 total. This list may not reflect recent changes .

  5. Takeda's treatment becomes first oral therapy for esophageal ...

    www.aol.com/news/us-fda-approves-takedas-therapy...

    Takeda's treatment will be available in stick packs of 2 milligram doses by the end of February, the company said. The company has set wholesale acquisition cost for the therapy, given twice daily ...

  6. TAP Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/TAP_Pharmaceuticals

    Abbott and Takeda agreed to end the partnership in 2008, with Abbott keeping the rights to leuprorelin, which had sales in 2007 of $600 million and a patent expiring in 2015 and the approximately 300 employees who worked on the product, and Takeda keeping the rights to lansoprazole, which had sales of $2.3 billion in 2007 but was facing ...

  7. Wave Life Sciences, Takeda Discontinue Research On ... - AOL

    www.aol.com/news/wave-life-sciences-takeda...

    Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses. The amendment allows Wave to advance or partner CNS programs ...

  8. Baxalta - Wikipedia

    en.wikipedia.org/wiki/Baxalta

    In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company [6] [7] increasing the Baxalta share price over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36%, compared to the company's stock price on August 3. [ 8 ]

  9. Dying To Be Free - The Huffington Post

    projects.huffingtonpost.com/dying-to-be-free...

    Few if any of the hundreds of employees at the 15 facilities implementing the program are medical professionals, and because of this lack of a medical approach at the centers, the state doesn’t technically define what they offer as “treatment.” “We look at it as an education, self-help program,” said Mike Townsend, the head of ...